Introduction
Cancer is the third most common cause of death following cardiovascular disease and accident (Mohebbi et al., 2008; Moradpour and Fatemi, 2013) and gastrointestinal (GI) cancers are the most frequent cancers among males and second to females' breast cancer in Iran (Mohebbi et al., 2011) . The epidemiological characteristic of upper GI cancer has markedly changed over recent decades so that oesophageal (Otterstatter et al., 2012; Zhang et al., 2012; Lin et al., 2013) and gastric (Camargo et al., 2011; Dikshit et al., 2011; Lin et al., 2011; Nagini, 2012) cancers have been decreasing in many parts of the world. Although these malignancies remain an important public health problem as the leading cancers in Iran, there were considerable variations in the sub-site of upper GI cancer in different parts of the country (Taghavi et al.,2013; Mehrabani et al., 2013) . While, Ardabil province in northwest has the highest incidence of gastric cancer (GC) and oesophagogastric junction (OGJC) cancer (Sadjadi et al., 2003) , Golestan province in the northeast is an area with the highest incidence of oesophageal cancer (OC) in Iran and worldwide (Kamangar et al., 2007) .
Health-related quality of life (HRQL) as a routine outcome measure is being used increasingly in clinical settings (Kiebert et al., 2000; Lee and Chi, 2000; AsadiLari et al., 2004; Farooqui et al., 2013) , which is ideal for determining the efficacy and impact of cancer care. Robust Quality of Life Questionnaires (QLQ) have been developed and validated in the past decades to measure the HRQL of oesophageal and gastric cancers (Hasegawa and Yoshikawa, 2010) . Measuring HRQL in patients with cancer may help health professionals and caregivers to guide clinical decision making, to determine the efficacy and impact of cancer care and to identify the most troublesome symptoms and functional problems to alleviate patients to confront better with the disease (Ferrans, 2010) , including those with oesophageal cancer (Lin et al., 2012) .
The European Organization for Research and treatment of Cancer (EORTC) Quality of Life Group (QLG) has developed a modular approach to HRQL measurement in cancer clinical trials (Aaronson et al., 1993) . Generic cancer questionnaire of EORTC QLQ-C30 was supplemented by site-specific modules to increase sensitivity and specificity. EORTC QLG has developed the oesophagogastric (OG) site-specific Questionnaire (EORTC QLQ-OG25) to be used in patients with oesophageal, gastric and oesophagogastric junction cancers (Lagergren et al., 2007) . EORTC QLQ-OG25 had been validated in European and Mexican patients, where its reliability and validity had been established for HRQL measurement in patients with oesophageal, gastric and oesophagogastric junction cancers undergoing multimodal treatments and follow up (Lagergren et al., 2007; OnateOcana et al., 2012; Tomaszewski et al., 2013) . The aim of present study was to examine the psychometric properties of translated version of EORTC QLQ-OG25 in Iranian patients.
Materials and Methods

Patients
This was a cross-sectional study conducted in the Medical Oncology Department of Mashhad University of Medical Sciences (MUMS). A consecutive group of patients with upper GI cancer were recruited into the study during September 2010 to April 2011, from two tertiary referral hospitals, a general hospital and a specific oncology hospital, in Mashhad, northeast of Iran. Participants over 18 years, with a histological diagnosis of adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of OC, GC and OGJC were included and those with concurrent malignancy, physical inability, a psychological or linguistic impairment, those refused to participate were excluded (Esmaili-Hesari et al., 2012) . Location of tumour, which was classified as OC, GC and OGJC according to Computed Tomography (CT) Scanning, Magnetic Resonance Imaging (MRI), endoscope findings and histopathology study in patients who underwent surgical resection. Clinical stage was defined according to TNM Staging System of American Joint Committee on Cancer (AJCC) (Edge and Compton, 2010) . The research protocol was approved by the ethical committee of IUMS and written informed consent was obtained from all patients' prior enrolment. Two hundred and seventy five patients took part in the study and six patients were excluded from our sample due to predetermined criteria; three patients refused to participate in the study without explanation, one patient had concurrent malignancy (breast cancer), one patient suffered from severe physical impairment (amputation feet) and one patient failed to complete the questionnaire (Esmaili-Hesari et al., 2012) .
Translation process
The Persian version of the EORTC QLQ-C30 questionnaire had been previously translated (Montazeri et al., 1999) . We followed the guidelines for translation and pilot study of the EORTC QLG (Koller et al., 2007 Questionnaires and data collection All participants completed the EORTC QLQ-C30 (version 3.0), EORTC QLQ-OG25 and demographic questionnaires. The QLQ-C30 is a self-report multidimensional general cancer-specific questionnaire, which measures the main factors influencing patients' lives (Fayers and Bottomley, 2002) . The QLQ-C30 is multidimensional, made up of 30 items with five function domains: physical, role, emotional, cognitive and social and one global health status/HRQL domain; three symptom domains including fatigue, nauseavomiting, pain, and six single items (Aaronson et al., 1993) . The core questionnaire, the EORTC QLQ-C30, is an extensively validated questionnaire, examined in multi-cultural clinical studies (Yun et al., 2004; Hoopman et al., 2006; Alawadhi and Ohaeri, 2010; Cheng et al., DOI:http://dx.doi.org/10.7314/APJCP.2014.15.6 
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2011; Kontodimopoulos et al., 2012) , including Iranian patients (Montazeri et al., 1999) . Responses to the core questionnaire and the modules were linearly converted into 0-100 scores using standard EORTC guidelines (Fayers et al., 2001) . For the five functional scales and the global QOL scale, a high score means "high level of functioning or global QOL". In case of symptom scales and single item, a higher score implies a "higher level of symptoms or problems" (Fayers et al., 2001) .
The QLQ-OG25 is a specific self-report questionnaire designed to assess the HRQL for oesophagogastric cancers. The EORTC QLQ-OG25 contains 25 items in six scales namely dysphagia, eating restrictions, reflux, odynophagia, pain and anxiety and ten single items; eating with others, dry mouth, sense of taste, body image, saliva, choking, cough, speech, weight loss and hair loss. The time frame of the QLQ-OG25 module is the precedent week (Lagergren et al., 2007) . The participants also completed a short questionnaire that recorded demographic characteristics and clinical features.
Timing of assessments
We recruited the patients undergoing different treatments modalities consecutively at the out-patient oncology clinics. Participants were instructed to complete the questionnaires themselves and illiterate patients were assisted by relatives or a trained interviewer. Test-retest reliability of the questionnaire was carried out on follow up group since their medical condition was expected to be more stable than those in active treatment, therefore 27 participants in follow up phase were asked to complete a second HRQL assessment between 7-14 days after the first administration of questionnaires.
Statistical analysis
Defining the HRQL scales and items in the QLQ-OG25: questionnaire responses were initially analyzed to establish the scale structure of the QLQ-OG25. Tests of clinical and psychometric validity were performed using the finalized scales and single items. Multi-trait scaling analysis was used to test whether the items of the QLQ-OG25 fitted with the proposed scale structure. Item convergent validity was defined as item-scale correlation of 0.40 or greater and item discriminant validity was indicated when an item had a higher correlation with another scale than with its own scale. Scaling errors were considered to occur when items consistently correlated more highly with another scale or did not correlate with any of the hypothesized scales.
Reliability:Internal consistency and test-retest analysis were performed to examine the reliability. Internal consistency was measured by Cronbach's alpha coefficient with a magnitude over 0.70 being considered acceptable for group comparisons. The test-retest (reproducibility) of the QLQ-OG25 was examined between the first and second test-retest assessments in patients reporting stable health status. Values of ICC vary between zero (totally unreliable) to 1 (perfectly reliable). For stability, reliability coefficient of 0.70 is generally considered acceptable, 0.80 is good, and 0.90 or high is excellent (Lagergren et al., 2007 ; Onate-Ocana et al., 2012; Tomaszewski et al., 2013) .
Validity: convergent validity and clinical validity were conducted to examine scale validity. Correlations between the QLQ-OG25 scales and single items were examined using Pearson's product moment correlation. Pearson's values of greater than 0.40 between an item and its own scale were considered highly correlated as evidence of item convergent validity. It was anticipate that the scales in QLQ-OG25 module would not be expected to relate to generic aspects of HRQL unless they addressed similar themes such as symptom scales (Lagergren et al., 2007; Onate-Ocana et al., 2012; Tomaszewski et al., 2013) .
Clinical validity: Known group comparisons examined the extent to which the QLQ-OG25 scores were able to discriminate between subgroups of clinically distinct patients. The clinical parameter hypothesized to form mutually exclusive patient subgroups for comparison included treatment intent (curative and palliative) and tumour stages. It was hypothesized that the patients with lower stage and those in curative group would report better functioning and less symptoms than patients in palliative care. These differences between groups were tested with Chi-square, one way analysis (ANOVA) and student t-test, as appropriate (Lagergren et al., 2007; Onate-Ocana et al., 2012; Tomaszewski et al., 2013) .
Results
Patient's socio-demographic and clinical characteristics
In all, 275 patients completed the Persian version Table  1 . At interview, time since diagnosis ranged from 2 to 396 months (Mean=15.5, SD=29.6 and median=6 months). All patients completed the questionnaire during a faceto-face interview. The questionnaire was well accepted by the patient population after minor changes resulted from patient's opinion in pilot studies. The majority of patients completed both questionnaires in less than 30 minutes in a calm environment. Reliability: Cronbach's alpha coefficient ranged from 0.76-0.89 (Table 2) . Test-retest scores were consistent and intra-class correlation coefficient (ICC) values ranged from 0.85 for OGDYS scale to 0.98 for OGPD scale for the QLQ-OG25 which indicated acceptable reliability.
Validity:There was a desirable correlation between each item and its own scale leading support to its itemcomponent validity and as shown in Tables 3 and 4 the correlation between an item and its own scale was significantly higher than its correlation with other scales. Correlation between the OG25 module and the QLQ-C30 core questionnaire scales was examined to demonstrate differences and clinical meaning for all patients. Most scales in the QLQ-OG25 were weakly correlated with the QLQ-C30 scales. The dysphagia scale (OGDYS) was moderately correlated with QLQ-C30 fatigue (r=0.50) and eating restrictions scale (OGEAT) was moderately correlated with QLQ-C30 physical function (r=-0.51), role function (r=-0.51), nausea and vomiting (r=0.56), pain (r=0.61), global health (r=-0.53) scales and appetite loss (r=0.64). Likewise, reflux scale was moderately correlated with nausea and vomiting (r=0.51) and anxiety with emotional function scales (r=-0.55). The odynophagia scale was correlated with emotional function (r=-0.54), fatigue (r=0.52) and pain scales (r=0.53). These correlations demonstrate the clinical overlap between the subscales which were expected. Table 5 summarizes the results of known-group comparisons. We merged patients with stage I and II because of a small number of patients in stage I tumour (Table  5 ). According to tumour site, clinically distinct groups did not demonstrate statistical differences. :http://dx.doi.org/10.7314/APJCP.2014.15.6 
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Discussion
These results present the validation process of Persian version of EORTC QLQ-OG25 which is designed to assess the quality of life of patients with upper GI cancers as a supplement to the EORTC QLQ-C30, which confirm the cross-cultural validity of EORTC QLQ-OG25 in Iranian patients as the second validation report outside the Europe (Onate-Ocana et al., 2012) . In other hand, this report is important because of high frequency of upper GI cancer in Iran and recent increasing incidence of oesophagogastric junction cancer in this country (Taghavi et al., 2007; Mousavi et al., 2009; Mohagheghi et al., 2009) .
Minor associations between scales in the QOL-C30 and the QOL-OG25 indicate that the specific module (OG-25) addresses different issues from the core questionnaire aspects. The QLQ-OG25 demonstrated acceptable psychometric property and its clinical validity supports its use to supplement the core questionnaire to assess quality of life in patients with different stages of upper GI a-groups of tumour stage I &II r merged because of small number in stage I(n=6); b-P value derived from ANOVA was used to determine if differences were statistically significant at the 1% level; c-P value derived from t-test which used to determine if differences were statistically significant at the 1% level; d-scores range from 0-100 with higher score indicating better conditions; e-scores range from 0-100 with higher score indicating worse conditions and greater level of symptoms cancers undergoing multi-modal treatment either palliative or potentially curative treatments (Lagergren et al., 2007; Onate-Ocana et al., 2012; Tomaszewski et al., 2013) . The multi-trait scaling analysis confirmed six scales (dysphagia, eating restrictions, reflux, odynophagia, pain and discomfort and anxiety) and ten single items (eating with other, dry mouth, sense of taste, body image, saliva, chocking, cough, speech, weight loss and hair loss). Generally, the reliability of the Persian version of the QLQ-OG25 was very good and the reliability (Chronbach's alpha coefficient) of six component of QLQ-OG25 was higher than the originally report (Lagergren et al., 2007) and Onate-Ocana finding (Onate-Ocana et al., 2012) , however, similar to those reports, reliability of reflux scale is lower than the other QLQ-OG25 scales in all tumour sites but in gastric cancer in the current study.
The module and core questionnaire were sensitive to clinical differences and were able to discriminate between clinically distinct groups of patients such as patients in different tumour stages and treatment intent groups. Similar finding has been reported in MexicanSpanish version of the questionnaire (Onate-Ocana et al., 2012) as well as in the original version in English (Lagergren et al., 2007) , where the instrument was able to clinically distinguish distinct groups. Although the QLQ-OG25 better distinguished between tumour stages as well as curative and palliative groups, inversely, there was no statistical difference amongst clinically distinct groups except according to tumour site (Onate-Ocana et al., 2012) . In the Polish experience with 98 OG cancer patients, no statistical differences were detected in OG-25 scales, (Tomaszewski et al., 2013) which indicate that our findings were superior to the similar studies, which can be attributable to the larger sample size and also more clinically distinction. There was a minor statistical difference in two previous studies in social function, pain and discomfort, eating with other, saliva and speech (Lagergren et al., 2007) , pain and discomfort and trouble with coughing (Onate-Ocana et al., 2012) , which were dissimilar to our findings. Further studies are also needed to confirm the anticipated sensitivity to change over time in Iranian patients.
After minor changes resulted from patients' opinions in our pilot studies, patient's acceptance was well and we did not notice any problem when it was administered to the Persian language patients who indicated the translation was satisfactory and understandable. As the recent research has shown important advances in neoadjuvant and adjuvant in treatment patients with upper GI cancers (Matuschek et al., 2011; Ku and Ilson, 2012; Xu et al., 2012; Schuhmacher et al., 2013) , it was suggested, HRQL measurement evaluated as the most important outcome in oncology patients undergoing different treatment procedure.
In conclusion, the Persian version of QLQ-OG25 has acceptable psychometric properties and is recommended to be administered, together with the core questionnaire, in patients with upper GI cancers. The QLQ-OG25 tool has the capability to distinguish between various treatments modalities, which supports its benefit in routine administration to upper-gastrointestinal (GI) cancer patients.
